Giant Cell Arteritis Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

The Giant Cell Arteritis Market is Segmented by Therapy Type (Biologic Therapies, Corticosteroids, Immunosuppressants, Pipeline Therapies), Disease Stage (Newly Diagnosed Giant Cell Arteritis, and More), Route of Administration (Oral, Intravenous, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts Provided in Terms of Value (USD).

Giant Cell Arteritis Market Size and Share

Giant Cell Arteritis Market Size
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Giant Cell Arteritis Market Analysis by Mordor Intelligence

The Giant Cell Arteritis Market size is projected to expand from USD 1.90 billion in 2026 to USD 2.02 billion in 2027, and to reach USD 2.89 billion by 2032, registering a CAGR of 7.43% between 2027 and 2032. Giant cell arteritis is the most prevalent primary systemic vasculitis among adults aged 50 years and older, and delayed treatment can result in permanent vision loss. Aging populations in Western countries and East Asia are enlarging the treated patient pool. Oral JAK inhibitor approval has broadened steroid-sparing treatment choices, while fast-track diagnostic pathways are reducing the time before therapy begins. These changes bring more previously unrecognized patients into formal treatment and create opportunities across drug access, distribution, and follow-up care. The giant cell arteritis market also faces uneven reimbursement decisions, biosimilar price pressure, and continued use of corticosteroid-first protocols in community rheumatology.

Key Report Takeaways

  • By therapy type, biologic therapies held 48.3% of the giant cell arteritis market share in 2026, while corticosteroids are forecast to grow at a CAGR of 8.12% through 2032.
  • By disease stage, newly diagnosed giant cell arteritis accounted for 44.25% of the giant cell arteritis market in 2026, while relapsing giant cell arteritis is projected to expand at a CAGR of 9.25% through 2032.
  • By route of administration, intravenous held 41.16% of the giant cell arteritis market share in 2026, while the oral route is forecast to grow at a CAGR of 7.84% through 2032.
  • By distribution channel, hospital pharmacies accounted for 46.52% of the giant cell arteritis market in 2026, while online pharmacies are projected to grow at a CAGR of 8.63% through 2032.
  • By geography, North America held 47.15% of the market share in 2026, while Asia-Pacific is forecast to grow at a CAGR of 10.26% through 2032.

Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.

Giant Cell Arteritis Market Segment Analysis

By Therapy Type:

Biologics Lead While Corticosteroids Retain a Treatment Role

Biologic therapies held 48.31% of the giant cell arteritis market share in 2026, supported by tocilizumab’s long-standing position in GCA care. Tocilizumab had been the only approved biologic for GCA before 2025. IL-6 receptor inhibitors form the largest part of this category. Monoclonal antibodies and other targeted immunotherapies provide adjacent treatment options. Corticosteroids are forecast to be the fastest-growing therapy type at a CAGR of 8.12% through 2032. They remain the universal treatment backbone, including when used with biologic therapy.

Low-dose maintenance protocols also sustain corticosteroid use while clinicians work toward steroid-free remission. Immunosuppressants such as methotrexate, azathioprine, and mycophenolate mofetil remain second-line steroid-sparing choices for patients who cannot use biologics. Methotrexate retains practical relevance because of its established safety profile and lower acquisition cost. Pipeline therapies include JAK inhibitors, GM-CSF inhibitors, and new small molecules.

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

Giant Cell Arteritis Market Share by Therapy Type, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Giant Cell Arteritis Market Share by Therapy Type, 2026

By Disease Stage:

Relapsing Disease Extends Treatment Demand

Newly diagnosed GCA represented 44.25% of the giant cell arteritis market in 2026. This segment includes large-vessel GCA, cranial GCA, and early-stage presentations among older adults entering treatment. Fast-track diagnostic pathways can enlarge this segment by identifying cases that were previously missed. Relapsing giant cell arteritis is forecast to grow at a CAGR of 9.25% through 2032. Its pace reflects the growing importance of recurrent, steroid-dependent, and refractory disease in treatment decisions.

Relapsing patients often require therapy for several years and are an important group for newer treatments. In the SELECT-GCA extension, continuous upadacitinib maintained remission from weeks 52 to 104 in 67.3% of patients. These findings support long-duration treatment strategies in appropriate patients. Complicated GCA includes vision-threatening disease, aortic involvement, and systemic vasculitis. This group has the highest treatment intensity and uses multimodal imaging and combination treatment protocols more often.

By Route of Administration:

Oral Access Changes Care Delivery

Intravenous administration held 41.16% of the giant cell arteritis market share in 2026. The segment remains supported by established hospital-based tocilizumab infusion protocols. In the United States, Medicare Part B coverage historically allowed access to intravenous biologics without prior authorization for many beneficiaries. Oral administration is expected to grow at a CAGR of 7.84% through 2032. Upadacitinib’s 2025 approval introduced the first once-daily oral GCA therapy and changed treatment options outside academic infusion centers.

Subcutaneous administration combines home injection convenience with established experience using subcutaneous tocilizumab. Other routes, mainly intramuscular corticosteroid delivery, serve a stable clinical niche. The movement from intravenous therapy toward oral and subcutaneous options changes where dispensing takes place. Treatments delivered outside hospitals can shift procurement toward retail and digital pharmacy channels. 

Segment this market the way your business does.

Get tailored market insights for your requirements.

Giant Cell Arteritis Market Share by Route of Administration, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Giant Cell Arteritis Market Share by Route of Administration, 2026

By Distribution Channel:

Hospital Pharmacies Remain Central as Digital Fulfillment Expands

Hospital pharmacies accounted for 46.52% of the giant cell arteritis market in 2026. Their position is linked to the procurement of intravenous biologics and specialty medicines requiring supervised administration. As long as intravenous therapies are widely used, hospitals retain control over substantial medicine spending. Online pharmacies are expected to grow at a CAGR of 8.63% through 2032. Oral and subcutaneous therapies expand eligibility for specialty mail-order and digital fulfillment. This makes the distribution strategy increasingly important for manufacturers entering the giant cell arteritis market.

Retail pharmacies provide dispensing for oral corticosteroids and generic immunosuppressants, especially at earlier or less complex stages of treatment. Hospital pharmacies are unlikely to lose their leading role in intravenous biologic dispensing. Biosimilar coverage policies can also influence which channel fills a prescription and which product is selected. The outcome depends on payer rules, prescriber preference, and the route used for the prescribed therapy.

Geography Analysis

North America

North America accounted for 47.15% of the giant cell arteritis market share in 2026. The United States has dense subspecialty rheumatology networks and high biologic adoption. A 2025 study found that 74% of U.S. GCA patients were covered by Medicare or Medicare Advantage. The same study reported a 43-day mean delay between insurance approval and medication initiation, with a mean patient out-of-pocket spending of USD 1,023 after insurance for the first monthly fill. Canada’s drug agency issued a conditional positive recommendation for upadacitinib in February 2026, provided that total treatment costs do not exceed the tocilizumab price ceiling.

Europe

Europe is the second-largest regional block, with Germany, the United Kingdom, and France supporting biologic adoption. The United Kingdom’s use of EULAR-aligned fast-track clinic standards supports earlier diagnosis in secondary care. France and the Netherlands made unfavorable reimbursement decisions for upadacitinib in 2025. Those decisions create different access conditions across European healthcare systems. The giant cell arteritis market in Europe, therefore, combines strong clinical infrastructure with uneven payer support for new oral therapies.

Asia-Pacific, the Middle East, Africa, and South America

Asia-Pacific is projected to be the fastest-growing region at a CAGR of 10.26% through 2032. China’s approval of tocilizumab for GCA opened the biologic treatment category within the country. China’s Healthy China 2030 initiative includes the development of specialist capacity for autoimmune disease care. South Korea and Australia also support regional growth through treatment demand and clinical research participation. The Middle East, Africa, and South America remain smaller regions with corticosteroid-led treatment patterns and limited biologic access outside major tertiary centers. Saudi Arabia, the United Arab Emirates, Brazil, and South Africa provide important access points, although diagnostic capacity and public procurement limits remain material constraints.

Giant Cell Arteritis Market Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market Concentration

Giant Cell Arteritis Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

The giant cell arteritis market is moderately concentrated around tocilizumab from Roche and Genentech and upadacitinib from AbbVie. These therapies shape the current biologic and targeted treatment setting. Novartis reported in July 2025 that secukinumab did not achieve the primary endpoint in the Phase III GCAptAIN trial. The result reduced the near-term role of IL-17A inhibition in GCA development. Competition is now centered more clearly on IL-6 receptor inhibitors and JAK-1 inhibitors. Tocilizumab biosimilars from Fresenius Kabi, Celltrion, and other manufacturers are increasing price competition in institutional procurement.

AbbVie expanded its position by receiving U.S. approval for upadacitinib in GCA in April 2025. The company also accumulated GCA-specific evidence through the ongoing TILT2 observational study in France beginning in March 2026. This supports a real-world evidence base for the oral treatment. Roche and biosimilar manufacturers are responding to a different commercial environment as lower-cost tocilizumab alternatives increase payer attention. The Giant Cell Arteritis industry includes price-based competition from biosimilars alongside differentiated competition from oral targeted therapies. Payer policies that allow biosimilar substitution can further redirect treatment volume toward lower-cost products.

A remaining treatment gap involves patients with moderate-to-severe relapsing or refractory disease who cannot use IL-6 receptor or JAK inhibitor therapy. Mavrilimumab from Kiniksa showed Phase II flare rates of 19%, compared with 46% for placebo. Phase III development had not begun, and the termination of MedImmune’s global licensing agreement in May 2025 left the asset without an established Phase III path. Sanofi’s sarilumab remains a clinical option for some patients who experience tocilizumab-related adverse events. Its Phase III program was discontinued after recruitment delays related to COVID-19.

Giant Cell Arteritis Industry Leaders

  1. F. Hoffmann-La Roche Ltd.

  2. AbbVie Inc.

  3. Biogen Inc.

  4. Fresenius Kabi AG

  5. Celltrion Inc.

  6. *Disclaimer: Major Players sorted in no particular order

Giant Cell Arteritis Market Companies Covered in this Report

  • Abbvie
  • Amgen
  • Biogen
  • Bristol-Myers Squibb
  • Celltrion
  • Dr. Reddy’s Laboratories
  • Eli Lilly and Company
  • Fresenius
  • Roche
  • Johnson & Johnson
  • Kiniksa Pharmaceuticals, Ltd.
  • MorphoSys AG
  • Novartis
  • Pfizer
  • Sanofi
  • Sobi AB
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical Industries
  • UCB

Recent Industry Developments in Giant Cell Arteritis Market

  • July 2026: Poland's Agency for Health Technology Assessment (AOTMiT) issued President Recommendation 90/2026 supporting positive reimbursement of upadacitinib (Rinvoq) for adult GCA patients, expanding reimbursed access to JAK inhibitor therapy in a Central European market of approximately 38 million people.
  • April 2026: Japan's Ministry of Health, Labor and Welfare officially designated GCA as an intractable disease number 41, creating a formal medical expense support program for eligible patients and establishing national diagnosis registry requirements, a move that structurally expands reimbursed pharmaceutical access for the Japanese GCA patient population.
  • February 2026: Canada’s Drug Agency issued a conditional positive reimbursement recommendation for upadacitinib for GCA, requiring total treatment costs not to exceed those of tocilizumab and limiting prescribing to rheumatologists experienced in GCA management.

Table of Contents for Giant Cell Arteritis Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Aging Population and Rising GCA Incidence
    • 4.2.2 Expansion of Steroid-Sparing Biologic Therapy
    • 4.2.3 Greater Use of Vascular Imaging and Fast-Track Diagnostic Pathways
    • 4.2.4 Increasing Clinical Development and Targeted-Therapy Investment
    • 4.2.5 Growing Demand for Oral and Home-Administered Therapies
  • 4.3 Market Restraints
    • 4.3.1 Corticosteroid-Related Toxicity and Monitoring Burden
    • 4.3.2 High Cost and Restricted Reimbursement for Targeted Therapies
    • 4.3.3 Delayed Referral and Specialist Capacity Constraints
  • 4.4 Supply Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Therapy Type
    • 5.1.1 Biologic Therapies
    • 5.1.1.1 Interleukin-6 Inhibitors
    • 5.1.1.2 Monoclonal Antibody Therapies
    • 5.1.1.3 Targeted Immunotherapies
    • 5.1.2 Corticosteroids
    • 5.1.2.1 Oral Corticosteroids
    • 5.1.2.2 Intravenous Corticosteroids
    • 5.1.2.3 Low-dose Maintenance Therapy
    • 5.1.3 Immunosuppressants
    • 5.1.3.1 Methotrexate
    • 5.1.3.2 Azathioprine
    • 5.1.3.3 Mycophenolate Mofetil
    • 5.1.4 Pipeline Therapies
    • 5.1.4.1 JAK Inhibitors
    • 5.1.4.2 GM-CSF Inhibitors
    • 5.1.4.3 Novel Small Molecules
  • 5.2 By Disease Stage
    • 5.2.1 Newly Diagnosed Giant Cell Arteritis
    • 5.2.1.1 Cranial Giant Cell Arteritis
    • 5.2.1.2 Large-vessel Giant Cell Arteritis
    • 5.2.1.3 Early-stage Disease
    • 5.2.2 Relapsing Giant Cell Arteritis
    • 5.2.2.1 Recurrent Disease
    • 5.2.2.2 Steroid-dependent Disease
    • 5.2.2.3 Refractory Disease
    • 5.2.3 Complicated Giant Cell Arteritis
    • 5.2.3.1 Vision-threatening Disease
    • 5.2.3.2 Aortic Involvement
    • 5.2.3.3 Systemic Vasculitis
  • 5.3 By Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Intravenous
    • 5.3.3 Subcutaneous
    • 5.3.4 Other Routes of Administration
  • 5.4 By Distribution Channel
    • 5.4.1 Hospital Pharmacies
    • 5.4.2 Retail Pharmacies
    • 5.4.3 Online Pharmacies
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
    • 6.3.1 AbbVie Inc.
    • 6.3.2 Amgen Inc.
    • 6.3.3 Biogen Inc.
    • 6.3.4 Bristol-Myers Squibb Company
    • 6.3.5 Celltrion Inc.
    • 6.3.6 Dr. Reddy's Laboratories Limited
    • 6.3.7 Eli Lilly and Company
    • 6.3.8 Fresenius Kabi AG
    • 6.3.9 F. Hoffmann-La Roche Ltd.
    • 6.3.10 Johnson & Johnson
    • 6.3.11 Kiniksa Pharmaceuticals, Ltd.
    • 6.3.12 MorphoSys AG
    • 6.3.13 Novartis AG
    • 6.3.14 Pfizer Inc.
    • 6.3.15 Sanofi
    • 6.3.16 Sobi AB
    • 6.3.17 Takeda Pharmaceutical Company Limited
    • 6.3.18 Teva Pharmaceutical Industries Ltd.
    • 6.3.19 UCB S.A.

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment

Global Giant Cell Arteritis Market Report Scope

According to the report’s scope, the giant cell arteritis market refers to the industry focused on therapies and diagnostics for giant cell arteritis, an inflammatory disease of blood vessels that can cause vision loss and other serious complications. It includes corticosteroids, biologics, and emerging targeted treatments, with growth driven by the rising prevalence among aging populations, advances in immunology, and increasing awareness of early diagnosis.

The giant cell arteritis market is segmented into therapy type, disease stage, route of administration, distribution channel, and geography. By therapy type, the market is segmented into biologic therapies, corticosteroids, immunosuppressants, and pipeline therapies. The biologic therapies are further segmented into interleukin-6 inhibitors, monoclonal antibody therapies, and targeted immunotherapies. The corticosteroids are further segmented into oral corticosteroids, intravenous corticosteroids, and low-dose maintenance therapy. The immunosuppressants are further segmented into methotrexate, azathioprine, and mycophenolate mofetil. The pipeline therapies are further segmented into JAK inhibitors, GM-CSF inhibitors, and novel small molecules. By disease stage, the market is segmented into newly diagnosed giant cell arteritis, relapsing giant cell arteritis, and complicated giant cell arteritis. The newly diagnosed giant cell arteritis is further segmented into cranial giant cell arteritis, large-vessel giant cell arteritis, and early-stage disease. The relapsing giant cell arteritis is further segmented into recurrent disease, steroid-dependent disease, and refractory disease. The complicated giant cell arteritis is further segmented into vision-threatening disease, aortic involvement, and systemic vasculitis. By route of administration, the market is segmented into oral, intravenous, subcutaneous, and other routes of administration. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers values (USD) for all the above segments.  

Segmentation Overview

By Therapy Type
Giant Cell Arteritis Market segmentation breakdown
Biologic Therapies Interleukin-6 Inhibitors
Monoclonal Antibody Therapies
Targeted Immunotherapies
Corticosteroids Oral Corticosteroids
Intravenous Corticosteroids
Low-dose Maintenance Therapy
Immunosuppressants Methotrexate
Azathioprine
Mycophenolate Mofetil
Pipeline Therapies JAK Inhibitors
GM-CSF Inhibitors
Novel Small Molecules
By Disease Stage
Giant Cell Arteritis Market segmentation breakdown
Newly Diagnosed Giant Cell Arteritis Cranial Giant Cell Arteritis
Large-vessel Giant Cell Arteritis
Early-stage Disease
Relapsing Giant Cell Arteritis Recurrent Disease
Steroid-dependent Disease
Refractory Disease
Complicated Giant Cell Arteritis Vision-threatening Disease
Aortic Involvement
Systemic Vasculitis
By Route of Administration
Giant Cell Arteritis Market segmentation breakdown
Oral
Intravenous
Subcutaneous
Other Routes of Administration
By Distribution Channel
Giant Cell Arteritis Market segmentation breakdown
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Geography
Giant Cell Arteritis Market segmentation breakdown
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Giant Cell Arteritis Market segmentation breakdown
By Therapy Type Biologic Therapies Interleukin-6 Inhibitors
Monoclonal Antibody Therapies
Targeted Immunotherapies
Corticosteroids Oral Corticosteroids
Intravenous Corticosteroids
Low-dose Maintenance Therapy
Immunosuppressants Methotrexate
Azathioprine
Mycophenolate Mofetil
Pipeline Therapies JAK Inhibitors
GM-CSF Inhibitors
Novel Small Molecules
By Disease Stage Newly Diagnosed Giant Cell Arteritis Cranial Giant Cell Arteritis
Large-vessel Giant Cell Arteritis
Early-stage Disease
Relapsing Giant Cell Arteritis Recurrent Disease
Steroid-dependent Disease
Refractory Disease
Complicated Giant Cell Arteritis Vision-threatening Disease
Aortic Involvement
Systemic Vasculitis
By Route of Administration Oral
Intravenous
Subcutaneous
Other Routes of Administration
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America

Key Questions Answered in the Report

What is driving growth in the giant cell arteritis treatment market?

Aging populations, earlier diagnosis, and wider use of steroid-sparing therapies support treatment demand. The giant cell arteritis market is forecast to grow from USD 1.90 billion in 2026 to USD 2.02 billion in 2027 and to reach USD 2.89 billion by 2032, at a 7.43% CAGR from 2027 to 2032.

Which therapy type held the largest share in 2026?

Biologic therapies held 48.31% of revenue in 2026, led by the established role of tocilizumab.

Which disease stage is growing fastest?

Relapsing giant cell arteritis is projected to grow at a 9.25% CAGR through 2032 because recurring and refractory disease often needs longer treatment.

Which region is growing fastest for GCA therapies?

Asia-Pacific is forecasted to grow at a 10.26% CAGR through 2032, supported by expanding healthcare infrastructure and treatment access.

Page last updated on: